Joshua D. Ooi

246 Clayton Rd
Clayton, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

The future of TCR-Treg therapies is renewables.

The future of TCR-Treg therapies is renewables.

Journal: Autoimmunity reviews

Published: April 20, 2026

Assessment of pH-Responsive Ionisable Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer.

Assessment of pH-Responsive Ionisable Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer.

Journal: Pharmaceutics

Published: March 21, 2026

TCR recognition of peptide-HLA class II complexes in autoimmunity: Structural insights for therapeutic targeting.

TCR recognition of peptide-HLA class II complexes in autoimmunity: Structural insights for therapeutic targeting.

Journal: Journal of autoimmunity

Published: February 08, 2026

Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel Disease.

Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel Disease.

Journal: International journal of molecular sciences

Published: December 26, 2025

Characteristics of T-Cells Expressing IL-37 and Its Receptors in Inflammatory Bowel Disease.

Characteristics of T-Cells Expressing IL-37 and Its Receptors in Inflammatory Bowel Disease.

Journal: International journal of molecular sciences

Published: December 16, 2025

Editorial: Community series: systemic vasculitis: advances in pathogenesis and therapies, volume II.

Editorial: Community series: systemic vasculitis: advances in pathogenesis and therapies, volume II.

Journal: Frontiers in immunology

Published: December 12, 2025

Hybrid CARs: rewiring macrophage signaling for targeted therapy in acute and chronic kidney inflammation.

Hybrid CARs: rewiring macrophage signaling for targeted therapy in acute and chronic kidney inflammation.

Journal: Kidney international

Published: November 25, 2025

Risk factors for severe infections during induction therapy of patients with microscopic polyangiitis.

Risk factors for severe infections during induction therapy of patients with microscopic polyangiitis.

Journal: Clinical and experimental rheumatology

Published: November 19, 2025

The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis.

The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: October 06, 2025

Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis.

Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 29, 2025

Regulatory T cell therapy for myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis.

Regulatory T cell therapy for myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis.

Journal: Frontiers in immunology

Published: July 29, 2025

Cryptic but critical: non-canonical antigens in cancer immunotherapy.

Cryptic but critical: non-canonical antigens in cancer immunotherapy.

Journal: Trends in immunology

Published: June 03, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026